Docoh
Loading...

OPT Opthea Limited

Filed: 24 Feb 21, 6:08am

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of February 2021

Commission File Number: 001-39621

 

 

OPTHEA LIMITED

(Translation of registrant’s name into English)

 

 

Level 4

650 Chapel Street

South Yarra, Victoria 3141

Australia

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 


INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On February 24, 2021, Opthea Limited lodged a press release with the Australian Securities Exchange, announcing certain clinical updates relating to OPT-302. A copy of this press release is attached to this report on Form 6-K as Exhibit 99.1.

EXHIBITS

 

Exhibit  

Description

99.1  Press Release dated February 24, 2021


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  OPTHEA LIMITED
Date: February 24, 2021  By: 

/s/ Michael Tonroe

   Michael Tonroe
   Chief Financial Officer and Company Secretary